RAPT Therapeutics (RAPT) Stock Forecast & Price Target

$3.34

+0.22 (+7.05%)

(As of 07/26/2024 ET)

RAPT Therapeutics - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Hold
Based on 13 Analyst Ratings

Based on 13 Wall Street analysts who have issued ratings for RAPT Therapeutics in the last 12 months, the stock has a consensus rating of "Hold." Out of the 13 analysts, 9 have given a hold rating, and 4 have given a buy rating for RAPT.

Consensus Price Target

$24.67
638.52% Upside

High Forecast	$41.00
Average Forecast	$24.67
Low Forecast	$4.00

According to the 13 analysts' twelve-month price targets for RAPT Therapeutics, the average price target is $24.67. The highest price target for RAPT is $41.00, while the lowest price target for RAPT is $4.00. The average price target represents a forecasted upside of 638.52% from the current price of $3.34.

Type	Current Forecast 7/28/23 to 7/27/24	1 Month Ago 6/28/23 to 6/27/24	3 Months Ago 4/29/23 to 4/28/24	1 Year Ago 7/28/22 to 7/28/23
Consensus Rating	Hold	Hold	Moderate Buy	Buy
Strong Buy	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	4 Buy rating(s)	4 Buy rating(s)	6 Buy rating(s)	9 Buy rating(s)
Hold	9 Hold rating(s)	9 Hold rating(s)	6 Hold rating(s)	0 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$24.67	$24.67	$25.67	$40.60
Forecasted Upside	638.52% Upside	71.45% Upside	65.52% Upside	99.60% Upside

Get RAPT Therapeutics Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for RAPT and its competitors with MarketBeat's FREE daily newsletter.

Ad Crypto 101 Media

Next opportunity for crypto millions

The Bitcoin halving is the #1 creator of "crypto millionaires". That's because historically, every halving has led to a massive bull run in the year after it happens. That means we're in the "golden window" right now…

Check out the new "Crypto Bull Run Millionaire Blueprint" now!

RAPT Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

RAPT Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

RAPT Therapeutics Stock vs. The Competition

Type	RAPT Therapeutics	Medical Companies	S&P 500
Consensus Rating Score	2.31	2.72	2.50
Consensus Rating	Hold	Moderate Buy	Moderate Buy
Predicted Upside	638.52% Upside	3,123.38% Upside	9.16% Upside
News Sentiment Rating	Neutral News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
7/23/2024	HC Wainwright 3 of 5 stars	R. Selvaraju Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral
5/14/2024	Wolfe Research 3 of 5 stars		Reiterated Rating	Outperform ➝ Peer Perform
5/10/2024	Guggenheim 3 of 5 stars	Y. Suneja Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Neutral
5/10/2024	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Overweight ➝ Equal Weight	$13.00 ➝ $4.00	-14.16%
3/27/2024	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Neutral ➝ Neutral	$15.00 ➝ $13.00	+51.52%
2/22/2024	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Buy ➝ Neutral	$61.00 ➝ $10.00	-1.77%
Get the Latest News and Ratings for RAPT and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for RAPT Therapeutics and its competitors with MarketBeat's FREE daily newsletter.
2/21/2024	Leerink Partnrs Subscribe to MarketBeat All Access for the recommendation accuracy rating	T. Smith Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Outperform ➝ Market Perform
2/21/2024	SVB Leerink Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Outperform ➝ Market Perform	$42.00 ➝ $10.00	+45.56%
2/20/2024	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	P. Agrawal Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Overweight ➝ Neutral
2/16/2024	Evercore ISI Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Outperform
9/14/2023	Berenberg Bank Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Buy	$34.00	+77.64%
8/14/2023	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Overweight ➝ Overweight	$28.00 ➝ $31.00	+29.33%
8/8/2023	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Buy	$40.00	+77.15%
3/15/2023	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Buy	$27.00 ➝ $23.00	+20.73%
1/4/2023	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Overweight	$55.00 ➝ $48.00	+157.93%
9/21/2022	Capital One Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Z. Jallah Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$48.00	+98.76%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Saturday at 05:33 AM ET.

RAPT Forecast - Frequently Asked Questions

What is RAPT Therapeutics' forecast for 2024?: According to the research reports of 13 Wall Street equities research analysts, the average twelve-month stock price forecast for RAPT Therapeutics is $24.67, with a high forecast of $41.00 and a low forecast of $4.00.
Should I buy or sell RAPT Therapeutics stock right now?: 13 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for RAPT Therapeutics in the last twelve months. There are currently 9 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" RAPT shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in RAPT, but not buy additional shares or sell existing shares.
Does RAPT Therapeutics's stock price have much upside?: According to analysts, RAPT Therapeutics's stock has a predicted upside of 71.45% based on their 12-month stock forecasts.
Has RAPT Therapeutics been downgraded by Wall Street analysts recently?: Over the previous 90 days, RAPT Therapeutics's stock had 2 downgrades by analysts.
What analysts cover RAPT Therapeutics?: RAPT Therapeutics has been rated by research analysts at Barclays, Guggenheim, HC Wainwright, and Wolfe Research in the past 90 days.
Do Wall Street analysts like RAPT Therapeutics more than its competitors?: Analysts like RAPT Therapeutics less than other "medical" companies. The consensus rating for RAPT Therapeutics is Hold while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how RAPT compares to other companies.